<?xml version="1.0" encoding="UTF-8"?>
<supplementary-material content-type="local-data" id="MOESM5">
 <media xlink:href="12967_2018_1579_MOESM5_ESM.docx" xmlns:xlink="http://www.w3.org/1999/xlink">
  <caption>
   <p>
    <bold>Additional file 5: Fig. S1.</bold> Impact of 
    <italic>UGT1A1*28</italic> or 
    <italic>*6</italic> on event-free survival (EFS) in AML patients. (a, d) comparison of EFS among genotypes of 
    <italic>UGT1A1*28</italic>. (b, e) comparison of among genotypes of 
    <italic>UGT1A1*6</italic>. (c, f) combined effects of 
    <italic>UGT1A1*28</italic> and 
    <italic>*6</italic> on EFS. 
    <bold>Fig. S2.</bold> Flow chart of the study population. 
    <bold>Fig. S3.</bold> Gene expression of 
    <italic>CDA</italic> and 
    <italic>UGT1A1</italic> mRNA in blasts from AML patients from the Cancer Genome Atlas (TCGA) dataset (n = 173). AML blast cells scarcely express 
    <italic>UGT1A1.</italic>
   </p>
  </caption>
 </media>
</supplementary-material>
